Targeting polo-like kinases: A promising therapeutic approac for cancer treatment

Research output: Contribution to journalReview articlepeer-review

143 Scopus citations

Abstract

Polo-like kinases (Plks) are a family of serine-threonine kinases that regulate multiple intracellular processes including DNA replication, mitosis, and stress response. Plk1, the most well understood family member, regulates numerous stages of mitosis and is overexpressed in many cancers. Plk inhibitors are currently under clinical investigation, including phase III trials of volasertib, a Plk inhibitor, in acute myeloid leukemia and rigosertib, a dual inhibitor of Plk1/phosphoinositide 3-kinase signaling pathways, in myelodysplastic syndrome. Other Plk inhibitors, including the Plk1 inhibitors GSK461364A, TKM-080301, GW843682, purpurogallin, and poloxin and the Plk4 inhibitor CFI-400945 fumarate, are in earlier clinical development. This review discusses the biologic roles of Plks in cell cycle progression and cancer, and the mechanisms of action of Plk inhibitors currently in development as cancer therapies.

Original languageEnglish
Pages (from-to)185-195
Number of pages11
JournalTranslational Oncology
Volume8
Issue number3
DOIs
StatePublished - 2015

Bibliographical note

Publisher Copyright:
© 2015 The Authors. Published by Elsevier Inc.

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Targeting polo-like kinases: A promising therapeutic approac for cancer treatment'. Together they form a unique fingerprint.

Cite this